At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 812 enrolled
Drug / intervention
Ferumoxytol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia
In Brief
A Phase 3 clinical trial evaluating Ferumoxytol and Placebo for Iron Deficiency Anemia. Completed, enrolled 812 participants across 182 sites in 6 countries.
Detailed Summary
To evaluate the efficacy and safety of intravenous (IV) ferumoxytol compared with placebo for the treatment of iron deficiency anemia (IDA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIron Deficiency Anemia
CountriesCanada, Hungary, India, Latvia, Poland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartJun 2010
Primary CompletionFeb 2012
Study CompletionOct 2012
TodayJul 2026
First PostedApr 30, 2010
Enrollment StartJun 19, 2010
Primary CompletionFeb 27, 2012
Study CompletionOct 22, 2012
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.2 years ago
Interventions
Ferumoxytoldrug
IV Ferumoxytol
Placeboother
IV Placebo